Understanding how myosin mutations cause heart disease
Official title: Modeling myosin mechanobiology towards understanding the mechanisms of hypertrophic cardiomyopathy
Funded at University of Michigan at Ann Arbor · NIH-11013826 · Data updated 2026-11-12
This study is looking at how certain changes in a heart protein can cause thickening of the heart muscle in people with hypertrophic cardiomyopathy (HCM), and it aims to find better, personalized treatments for those affected by this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $249,000 |
| NIH project number | 5R00HL153679-05 |
| Project ID | NIH-11013826 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hypertrophic cardiomyopathy, particularly those with known mutations in beta cardiac myosin.
✕Less likely to help
Patients without hypertrophic cardiomyopathy or those whose condition is unrelated to myosin mutations may not benefit from this research.
What this research studies
This research investigates how specific mutations in beta cardiac myosin lead to hypertrophic cardiomyopathy (HCM), a condition characterized by heart muscle thickening. By examining the molecular and cellular mechanisms involved, the study aims to clarify how these mutations affect heart cell behavior and contribute to disease symptoms. The research employs advanced techniques such as CRISPR gene editing and computational modeling to analyze the effects of these mutations in a controlled environment. Ultimately, the goal is to develop more personalized treatment options for patients with HCM.
Why it matters
Potential benefit: If successful, this research could lead to more effective and tailored therapies for patients suffering from hypertrophic cardiomyopathy.
How similar studies have gone: Previous research has shown promise in understanding cardiac diseases through similar molecular and computational approaches, indicating a potential for success in this area.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Vander Roest, Alison Schroer — University of Michigan at Ann Arbor
- Study coordinator: Vander Roest, Alison Schroer
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.